Assessment of serum glucagon-like peptide-1 and dipeptidyl peptidase-4 levels in patients with migraine

Basit Öğe Kaydı
dc.contributor.authorGultekin, Melis
dc.contributor.authorDavran, Fatih
dc.contributor.authorYuksel, Nehir
dc.contributor.authorBeyazcicek, Ozge
dc.contributor.authorDemir, Serif
dc.date.accessioned2025-10-11T20:48:38Z
dc.date.available2025-10-11T20:48:38Z
dc.date.issued2025
dc.departmentDüzce Üniversitesien_US
dc.description.abstractBackground Migraine is a prevalent neurovascular disorder affecting over one billion people globally, imposing significant daily life limitations. Migraine headaches are linked to the activation of trigeminal nerve endings. Glucagon-like peptide-1 (GLP-1) is a hormone involved in insulin regulation and plays neuroprotective roles in the central nervous system (CNS). Dipeptidyl peptidase-4 (DPP-4) is a protease enzyme that degrades GLP-1, rendering it inactive, and modulates metabolic and neurological pathways. This study investigates the association between serum GLP-1 and DPP-4 levels and migraine pathophysiology to propose a novel therapeutic approach for migraine. Methods The study included 42 migraine patients and 42 healthy controls. After fasting for at least 8 h, blood samples were collected. Serum GLP-1 and DPP-4 levels were measured using ELISA, and statistical analyses were conducted with SPSS 24.0. Results Serum GLP-1 and DPP-4 levels were significantly lower in migraine patients compared to controls (p < 0.001). Patients with migraine with aura had significantly lower GLP-1 levels compared to those with migraine without aura (p = 0.016). A significant decrease in GLP-1 levels was observed in patients experiencing pain localized in the occipital lobe (p = 0.01). Conclusions Serum GLP-1 and DPP-4 levels were lower in migraine patients. Given the role of GLP-1 in the central nervous system, reduced GLP-1 may contribute to migraine pain. Similarly, low DPP-4, which metabolizes GLP-1, may be linked to these findings and could trigger attacks by increasing blood CGRP levels.en_US
dc.identifier.doi10.1007/s13760-025-02894-w
dc.identifier.issn0300-9009
dc.identifier.issn2240-2993
dc.identifier.pmid40999309en_US
dc.identifier.scopus2-s2.0-105016887020en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1007/s13760-025-02894-w
dc.identifier.urihttps://hdl.handle.net/20.500.12684/22032
dc.identifier.wosWOS:001580758800001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofActa Neurologica Belgicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKA_WOS_20250911
dc.subjectGLP-1en_US
dc.subjectDPP-4en_US
dc.subjectHeadacheen_US
dc.subjectMigraineen_US
dc.titleAssessment of serum glucagon-like peptide-1 and dipeptidyl peptidase-4 levels in patients with migraineen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu